ATLANTA -- After a long string of clinical trial success in hematologic malignancies, chimeric antigen receptor (CAR) T-cell therapy failed to improve event-free survival versus standard of care for primary refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
After a median follow-up of 10 months in the international phase III BELINDA trial, patients treated with tisagenlecleucel (tisa-cel, Kymriah) and those randomized to standard care had identical median event-free survival (EFS) of 3.0 months. Adjustment for potential imbalances in baseline characteristics did not substantively affect the results, which showed a hazard ratio of 0.95 for tisa-cel versus standard therapy (95% CI 0.72-1.25).
The explanation for the unexpected outcome "is a question that keeps me up every night," said Michael R. Bishop, MD, of the University of Chicago, during a late-breaking abstraction presentation at the American Society of Hematology (ASH) annual meeting.
He cited several possible answers: differences in trial design (including two positive studies reported at ASH), a liberal policy for use of bridging chemotherapy in BELINDA, substantial differences in time to infusion of CAR-T therapy, and different strategies for lymphodepleting therapy.
Responding to a question from the audience, Bishop said, "As you mentioned, tisa-cel has been very successful in other lines of diffuse large B-cell lymphoma, but I think our trial design did not permit it to have ultimate efficacy."
The results were reported simultaneously in the New England Journal of Medicine (NEJM).
Transformative Therapy
CAR T-cell therapy burst into the therapeutic landscape with two closely timed FDA approvals in the second half of 2017. The approvals stipulated later-line use of tisagenlecleucel and axicabtagene ciloleucel (axi-cel, Yescarta) in progressive leukemia and non-Hodgkin lymphoma (NHL), respectively. Since then, clinical investigators have pushed the envelope for earlier use to treat aggressive hematologic malignancies that many specialists believe will ultimate prove refractory and become fatal in most cases.
In two randomized trials reported at ASH, axi-cel and lisocabtagene maraleucel (liso-cel, Breyanzi) significantly improved EFS and progression-free survival (PFS), respectively, versus standard second-line therapy for progressive NHL (chemotherapy with or without stem-cell transplantation). Data from another trial reported at ASH showed that incorporating CAR T-cell therapy into first-line treatment of aggressive large B-cell lymphoma (LBCL) led to objective responses in 89% of patients, including complete responses (CRs) in 78%.
The BELINDA trial involved 322 transplant-eligible adults with primary refractory NHL or disease that had relapsed within 12 months of first-line treatment. The patients were randomized to tisa-cel or standard care chemotherapy. Patients allocated to CAR T-cell therapy could receive bridging therapy as needed to maintain disease control until T-cell infusion.
Patients who achieved a partial or complete response with standard-of-care therapy received additional chemotherapy, followed by high-dose chemotherapy and autologous stem-cell transplant. Patients who had stable or progressive disease with chemotherapy received additional chemoimmunotherapy, and selected patients were offered CAR T-cell therapy within constraints of the production process.
The primary endpoint was EFS, as assessed at 12 weeks. Secondary endpoints included objective response, safety, and cellular kinetics.
Before presenting the outcome data, Bishop noted the variable but generally prolonged time to infusion of CAR T-cell therapy. Median time to infusion was 52 days overall, including 41 days for U.S. patients and 57 days for patients outside the U.S. Two-thirds of patients enrolled in BELINDA were from outside the U.S. In contrast, the successful U.S.-based ZUMA-7 randomized trial reported at ASH had a median time to infusion of 27 days.
Almost half (48%) of the patients randomized to tisa-cel received more than one cycle of bridging chemotherapy, and only 17% received no bridging therapy, an indication of the prolonged time to CAR T-cell therapy infusion. Additionally, the overall response at 6 weeks was 38% in the tisa-cel arm and 54% in the control group. Almost twice as many patients in the tisa-cel arm had progressive disease at 6 weeks, prior to T-cell infusion (25.9% vs 13.8%). By 12 weeks, the response rates were 46% with tisa-cel and 42.5% with standard therapy.
The two treatment arms had similar rates of adverse events (AEs), treatment-related AEs, and serious AEs. Cytokine release syndrome (CRS) occurred in 58.6% of patients treated with tisa-cel, but only 4.9% of patients had grade 3 CRS. Neurologic events occurred in 10.3% of the tisa-cel arm, including grade 3 in 1.9%.
On-study mortality was 32.1% in the tisa-cel arm and 28.1% in the control group. Most deaths in both arms resulted from progressive disease, said Bishop. AE-related mortality was 6.2% with tisa-cel and 8.1% with the control treatment.
"Effective bridging therapy prior to CAR T-cel infusion and a shorter time to infusion for this chemotherapy-refractory patient population could be critical to improve outcomes," said Bishop. "Insights from this randomized phase III study should help guide optimal use of CAR T-cells in patients with relapsed/refractory aggressive non-Hodgkin lymphoma requiring second-line therapy and design of future CAR-T trials."
What Went Wrong?
Any suggested explanation for the study's negative outcome "would be pure speculation," said Frederick L. Locke, MD, of Moffitt Cancer Center in Tampa, Florida, who reported the successful ZUMA-7 results.
"One thing that's remarkable to me is that if you look at the standard-of-care arms in all three of these studies, they seem to be remarkably similar in terms of event-free survival," he told MedPage Today. "There are different rates of patients who got to transplant, but the ongoing event-free survival in all three studies with the standard of care was poor. For whatever reason, it appears that the CAR T-cell arm didn't perform as well as expected."
The disparate results from the trials reported at ASH show that patient selection for CAR T-cell therapy is important, said the authors of an accompanying NEJM editorial.
"What has been learned is that not all patients with 'relapsed or refractory large B-cell lymphoma' are the same," wrote Wyndham H. Wilson, MD, PhD, and Mark Roschewski, MD, of the Lymphoid Malignancies Branch of the National Cancer Institute, and NEJM deputy editor Dan L. Longo, MD. "Assessment of the curative potential of different constructs of CAR T cells will require comparisons in similar groups of patients, and differences in curative potential cannot be ruled out as contributing factors for the different outcomes of these trials."
Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow
Disclosures
BELINDA was supported by Novartis.
Bishop disclosed relationships with Kite-Gilead, AGIOS, Incyte, Bristol Myers Squibb, Sana Biotechnology, Therakos, Iovance Biotherapeutics, Novartis, CRISPR Therapeutics, and Autolus.
Longo is employed by NEJM.
Roschewski and Wilson disclosed no conflicts of interest.
More:
CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL - MedPage Today
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments